ContributorsPublishersAdvertisers

Clinical Challenges: First-Line Immunotherapy Eligibility in Advanced Bladder Cancer

MedPage Today
 2021-11-22

Cover picture for the articleThere are two immunotherapy options approved for first-line treatment of metastatic urothelial cancer in patients who are platinum-ineligible. In 2017, the FDA granted accelerated approvals to atezolizumab (Tecentriq) and pembrolizumab (Keytruda) for patients with advanced disease who are unable to receive cisplatin chemotherapy -- the recommended first-line option. "Currently,...

www.medpagetoday.com

Comments / 0

Comments / 0